CEL-SCI Corporation (CVM)

12.49 +0.21 (+1.71%) At close: 4:00PM EST

CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna, VA 22182
United States
703-506-9460
http://cel-sci.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Geert R. Kersten	CEO, Principal Accounting & Financial Officer, Treasurer and Director	607.02k	N/A	1959
Ms. Patricia B. Prichep	Sr. VP of Operations & Corp. Sec.	295k	N/A	1951
Dr. Eyal Talor	Chief Scientific Officer	376.39k	N/A	1956
Dr. Daniel H. Zimmerman	Sr. VP of Research & Cellular Immunology	249.58k	N/A	1941
Mr. John Cipriano	Sr. VP of Regulatory Affairs	202.68k	N/A	1942

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.

Corporate Governance

CEL-SCI Corporation’s ISS Governance QualityScore as of November 1, 2019 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.